Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1977 Mar;35(3):280–287. doi: 10.1038/bjc.1977.40

Cytotoxic antibody in acute myeloblastic leukaemia during immunotherapy: lack of tumour specificity.

D G Gale, I C MacLennan
PMCID: PMC2025282  PMID: 265730

Abstract

Cytotoxic antibodies to antigens specific for leukaemic myeloblasts have been sought in the serum of patients with acute myeloblastic leukaemia treated by immunotherapy with irradiated allogeneic myeloblasts and BCG. Assays of complement- and K-cell-mediated activity were used. Cytotoxicity to allogeneic myeloblasts was detected in both assays. When sera from 15 patients, taken at various times during immunotherapy, were systematically tested against a panel of 5 myeloblasts, the following patterns emerged: 1. No antibody was cytotoxic against all myeloblasts of the panel in either the K-cell or complement-dependent assay. However, all myeloblasts of the panel were lysed by a number of sera. 2. Cytotoxic antibody was detected as often against a panel of lymphocytes from healthy donors as against the panel of allogeneic myeloblasts. 3. Fresh and cryopreserved myeloblasts were equally susceptible to lysis in both assays. 4. Experiments failed to demonstrate any deterioration of cytotoxic antibody on storage. 5. The number of K-cell-revealed cytotoxic antisera increased with length of immunotherapy. This pattern was not apparent for antibodies revealed by complement. 6. No instance of cytotoxicity in either assay was seen when serum was tested against 12 autologous myeloblasts. It is considered that cytotoxic antibody detected with allogeneic myeloblasts is probably directed against HLA antigens common to immunizing and test target myeloblasts and target lymphocytes.

Full text

PDF
282

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker M. A., Ramachandar K., Taub R. N. Specificity of heteroantisera to human acute leukemia-associated antigens. J Clin Invest. 1974 Dec;54(6):1273–1278. doi: 10.1172/JCI107872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker M. A., Taub R. N., Brown S. M., Ramachandar K. Delayed cutaneous hypersensitivity in leukaemic patients to autologous blast cells. Br J Haematol. 1974 Aug;27(4):627–634. doi: 10.1111/j.1365-2141.1974.tb06629.x. [DOI] [PubMed] [Google Scholar]
  3. Currie G. A. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer. 1972 Jun;26(3):141–153. doi: 10.1038/bjc.1972.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gutterman J. U., Hersh E. M., Rodriguez V., McCredie K. B., Mavligit G., Reed R., Burgess M. A., Smith T., Gehan E., Bodey G. P., Sr Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet. 1974 Dec 14;2(7894):1405–1409. doi: 10.1016/s0140-6736(74)90070-1. [DOI] [PubMed] [Google Scholar]
  5. Hersey P., MacLennan I. C., Campbell A. C., Harris R., Freeman C. B. Cytotoxicity against human leukaemic cells. I. Demonstration of antibody-dependent lymphocyte killing of human allogeneic myeloblasts. Clin Exp Immunol. 1973 Jun;14(2):159–167. [PMC free article] [PubMed] [Google Scholar]
  6. Invernizzi G., Parmiani G. Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens. Nature. 1975 Apr 24;254(5502):713–714. doi: 10.1038/254713a0. [DOI] [PubMed] [Google Scholar]
  7. Klouda T. P., Lawler S. D., Powles R. L., Oliver R. T., Grant C. K. HL-A antibody response in patients with acute myelogenous leukaemia treated by immunotherapy. Transplantation. 1975 Mar;19(3):245–249. doi: 10.1097/00007890-197503000-00008. [DOI] [PubMed] [Google Scholar]
  8. MacLennan I. C., Gale D. G., Wood J. Resistance of certain leukaemic myeloblasts to immunological attack. Int J Cancer. 1975 Jun 15;15(6):995–999. doi: 10.1002/ijc.2910150616. [DOI] [PubMed] [Google Scholar]
  9. Powles R. L., Balchin L. A., Fairley G. H., Alexander P. Recognition of leukaemia cells as foreign before and after autoimmunization. Br Med J. 1971 Feb 27;1(5747):486–489. doi: 10.1136/bmj.1.5747.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Powles R. L., Crowther D., Bateman C. J., Beard M. E., McElwain T. J., Russell J., Lister T. A., Whitehouse J. M., Wrigley P. F., Pike M. Immunotherapy for acute myelogenous leukaemia. Br J Cancer. 1973 Nov;28(5):365–376. doi: 10.1038/bjc.1973.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Seigler H. F., Metzgar R. S., Mohanakumar T., Stuhlmiller G. M. Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. Fed Proc. 1975 Jul;34(8):1642–1646. [PubMed] [Google Scholar]
  12. Vogler W. R., Chan Y. K. Prolonging remission in myeloblastic leukemia by tice-strain bacillus Calmette-Guérin. Lancet. 1974 Jul 20;2(7873):128–131. doi: 10.1016/s0140-6736(74)91556-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES